Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-01-08

AUTHORS

Yanna-Marina Chevalme, Lotfi Boudali, Mathieu Gauthé, Caroline Rousseau, Andrea Skanjeti, Charles Merlin, Philippe Robin, Anne-Laure Giraudet, Marc Janier, Jean-Noël Talbot

ABSTRACT

IntroductionDespite growing evidence of a superior diagnostic performance of 68Ga-PSMA-11 over 18F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients. Our aims were to check (1) whether the excellent PR reported with PSMA-11 is also obtained in BCR patients whose recent FCH PET/CT was negative or equivocal; (2) in which biochemical and clinical context a high PSMA-11 PET/CT PR may be expected in those patients, in particular revealing an oligometastatic pattern; (3) whether among the various imaging protocols for PSMA-11 PET/CT used in France, one yields a significantly highest PR; (4) the tolerance of PSMA-11.Patients and methodsSix centres performed 68Ga-PSMA-11 PET/CTs during the first 3 years of its use in France. Prior to each PET/CT, the patient’s data were submitted prospectively for authorisation to ANSM, the French Medicine Agency. The on-site readings of 1084 PSMA-11 PET/CTs in BCR patients whose recent FCH PET/CTs resulted negative or equivocal were pooled and analysed.Results(1) The overall PR was 68%; for a median serum PSA level (sPSA) of 1.7 ng/mL, an oligometastatic pattern (1–3 foci) was observed in 31% of the cases overall; (2) PR was significantly related to sPSA (from 41% if < 0.2 ng/mL to 81% if ≥ 2 ng/mL), to patients’ age, to initial therapy (64% if prostatectomy vs. 85% without prostatectomy due to frequent foci in the prostate fossa), to whether FCH PET/CT was negative or equivocal (PR = 62% vs. 82%), and to previous BCR (PR = 63% for 1st BCR vs. 72% in case of previous BCR); (3) no significant difference in PR was found according to the imaging protocol: injected activity, administration of a contrast agent and/or of furosemide, dose length product, one single or multiple time points of image acquisition; (4) no adverse event was reported after PSMA-11 injection, even associated with a contrast agent and/or furosemide.ConclusionCompared with the performance of PSMA-11 PET/CT in BCR reported independently of FCH PET/CT in 6 large published series (n > 200), the selection based on FCH PET/CT resulted in no difference of PSMA-11 PR for sPSA < 1 ng/mL but in a slightly lower PR for sPSA ≥ 1 ng/mL, probably because FCH performs rather well at this sPSA and very occult BCR was over-represented in our cohort. An oligometastatic pattern paving the way to targeted therapy was observed in one fourth to one third of the cases, according to the clinico-biochemical context of the BCR. Systematic dual or triple acquisition time points or administration of a contrast agent and/or furosemide did not bring a significant added value for PSMA-11 PET/CT positivity and should be decided on individual bases. More... »

PAGES

2935-2950

References to SciGraph publications

  • 2015-11-12. Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2019-11-01. 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2019-09-06. Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2016-11-29. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-09-27. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2020-02-03. Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy—validation of a prediction model in EJNMMI RESEARCH
  • 2020-04-20. 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2020-03-10. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2017-03-10. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2017-05-12. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2018-06-19. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2018-10-22. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00259-020-05086-1

    DOI

    http://dx.doi.org/10.1007/s00259-020-05086-1

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1134446316

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/33416958


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Choline", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "France", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gallium Isotopes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gallium Radioisotopes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Recurrence, Local", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Positron Emission Tomography Computed Tomography", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prostate-Specific Antigen", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prostatic Neoplasms", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Direction des m\u00e9dicaments en oncologie, h\u00e9matologie, transplantation, n\u00e9phrologie, th\u00e9rapie cellulaire, produits sanguins, et radiopharmaceutiques, Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM), 143 Bd Anatole, F93200, St Denis, France", 
              "id": "http://www.grid.ac/institutes/grid.483743.f", 
              "name": [
                "Direction des m\u00e9dicaments en oncologie, h\u00e9matologie, transplantation, n\u00e9phrologie, th\u00e9rapie cellulaire, produits sanguins, et radiopharmaceutiques, Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM), 143 Bd Anatole, F93200, St Denis, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chevalme", 
            "givenName": "Yanna-Marina", 
            "id": "sg:person.013471630317.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013471630317.55"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Direction des m\u00e9dicaments en oncologie, h\u00e9matologie, transplantation, n\u00e9phrologie, th\u00e9rapie cellulaire, produits sanguins, et radiopharmaceutiques, Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM), 143 Bd Anatole, F93200, St Denis, France", 
              "id": "http://www.grid.ac/institutes/grid.483743.f", 
              "name": [
                "Direction des m\u00e9dicaments en oncologie, h\u00e9matologie, transplantation, n\u00e9phrologie, th\u00e9rapie cellulaire, produits sanguins, et radiopharmaceutiques, Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM), 143 Bd Anatole, F93200, St Denis, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Boudali", 
            "givenName": "Lotfi", 
            "id": "sg:person.012314332345.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012314332345.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de m\u00e9decine nucl\u00e9aire, H\u00f4pital Tenon, AP-HP Sorbonne Universit\u00e9, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.413483.9", 
              "name": [
                "Service de m\u00e9decine nucl\u00e9aire, H\u00f4pital Tenon, AP-HP Sorbonne Universit\u00e9, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gauth\u00e9", 
            "givenName": "Mathieu", 
            "id": "sg:person.01121730347.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121730347.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine Unit, ICO Ren\u00e9 Gauducheau, CNRS, Inserm, CRCINA, Nantes University, F-44000, Nantes, France", 
              "id": "http://www.grid.ac/institutes/grid.4817.a", 
              "name": [
                "Nuclear Medicine Unit, ICO Ren\u00e9 Gauducheau, CNRS, Inserm, CRCINA, Nantes University, F-44000, Nantes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rousseau", 
            "givenName": "Caroline", 
            "id": "sg:person.01240530667.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine Department, Hospices Civils de Lyon, EA 3738, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France", 
              "id": "http://www.grid.ac/institutes/grid.413852.9", 
              "name": [
                "Nuclear Medicine Department, Hospices Civils de Lyon, EA 3738, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Skanjeti", 
            "givenName": "Andrea", 
            "id": "sg:person.01203037034.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203037034.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine Department, Cancer Center Jean PERRIN, Clermont-Ferrand, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Nuclear Medicine Department, Cancer Center Jean PERRIN, Clermont-Ferrand, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Merlin", 
            "givenName": "Charles", 
            "id": "sg:person.0636003365.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636003365.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de M\u00e9decine Nucl\u00e9aire, EA 3878 (GETBO), Centre Hospitalier R\u00e9gional et Universitaire de Brest, Universit\u00e9 de Bretagne Occidentale, Brest, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Service de M\u00e9decine Nucl\u00e9aire, EA 3878 (GETBO), Centre Hospitalier R\u00e9gional et Universitaire de Brest, Universit\u00e9 de Bretagne Occidentale, Brest, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Robin", 
            "givenName": "Philippe", 
            "id": "sg:person.01307140060.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307140060.86"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Nuclear Medicine Department LUMEN, L\u00e9on B\u00e9rard Cancer Center, Lyon, France", 
              "id": "http://www.grid.ac/institutes/grid.462282.8", 
              "name": [
                "Nuclear Medicine Department LUMEN, L\u00e9on B\u00e9rard Cancer Center, Lyon, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Giraudet", 
            "givenName": "Anne-Laure", 
            "id": "sg:person.0760027635.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760027635.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Comit\u00e9 permanent de l\u2019ANSM, M\u00e9dicaments de diagnostic et de m\u00e9decine nucl\u00e9aire, St Denis, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Nuclear Medicine Department, Hospices Civils de Lyon, EA 3738, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France", 
                "Comit\u00e9 permanent de l\u2019ANSM, M\u00e9dicaments de diagnostic et de m\u00e9decine nucl\u00e9aire, St Denis, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Janier", 
            "givenName": "Marc", 
            "id": "sg:person.0577012270.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577012270.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Comit\u00e9 permanent de l\u2019ANSM, M\u00e9dicaments de diagnostic et de m\u00e9decine nucl\u00e9aire, St Denis, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Service de m\u00e9decine nucl\u00e9aire, H\u00f4pital Tenon, AP-HP Sorbonne Universit\u00e9, Paris, France", 
                "Comit\u00e9 permanent de l\u2019ANSM, M\u00e9dicaments de diagnostic et de m\u00e9decine nucl\u00e9aire, St Denis, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Talbot", 
            "givenName": "Jean-No\u00ebl", 
            "id": "sg:person.07715603712.83", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07715603712.83"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00259-019-04548-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1122256860", 
              "https://doi.org/10.1007/s00259-019-04548-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-017-3711-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1085391295", 
              "https://doi.org/10.1007/s00259-017-3711-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-017-3670-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084020155", 
              "https://doi.org/10.1007/s00259-017-3670-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-016-3578-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002221535", 
              "https://doi.org/10.1007/s00259-016-3578-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2525-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010481232", 
              "https://doi.org/10.1007/s00259-013-2525-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-019-04505-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1120901331", 
              "https://doi.org/10.1007/s00259-019-04505-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-020-04718-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1125547439", 
              "https://doi.org/10.1007/s00259-020-04718-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13550-020-0595-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1124553996", 
              "https://doi.org/10.1186/s13550-020-0595-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-015-3240-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020308992", 
              "https://doi.org/10.1007/s00259-015-3240-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-018-4189-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1107767706", 
              "https://doi.org/10.1007/s00259-018-4189-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-018-4067-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1104899563", 
              "https://doi.org/10.1007/s00259-018-4067-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-020-04809-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1126836112", 
              "https://doi.org/10.1007/s00259-020-04809-8"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-01-08", 
        "datePublishedReg": "2021-01-08", 
        "description": "IntroductionDespite growing evidence of a superior diagnostic performance of 68Ga-PSMA-11 over 18F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients. Our aims were to check (1) whether the excellent PR reported with PSMA-11 is also obtained in BCR patients whose recent FCH PET/CT was negative or equivocal; (2) in which biochemical and clinical context a high PSMA-11 PET/CT PR may be expected in those patients, in particular revealing an oligometastatic pattern; (3) whether among the various imaging protocols for PSMA-11 PET/CT used in France, one yields a significantly highest PR; (4) the tolerance of PSMA-11.Patients and methodsSix centres performed 68Ga-PSMA-11 PET/CTs during the first 3 years of its use in France. Prior to each PET/CT, the patient\u2019s data were submitted prospectively for authorisation to ANSM, the French Medicine Agency. The on-site readings of 1084 PSMA-11 PET/CTs in BCR patients whose recent FCH PET/CTs resulted negative or equivocal were pooled and analysed.Results(1) The overall PR was 68%; for a median serum PSA level (sPSA) of 1.7 ng/mL, an oligometastatic pattern (1\u20133 foci) was observed in 31% of the cases overall; (2) PR was significantly related to sPSA (from 41% if < 0.2 ng/mL to 81% if \u2265 2 ng/mL), to patients\u2019 age, to initial therapy (64% if prostatectomy vs. 85% without prostatectomy due to frequent foci in the prostate fossa), to whether FCH PET/CT was negative or equivocal (PR = 62% vs. 82%), and to previous BCR (PR = 63% for 1st BCR vs. 72% in case of previous BCR); (3) no significant difference in PR was found according to the imaging protocol: injected activity, administration of a contrast agent and/or of furosemide, dose length product, one single or multiple time points of image acquisition; (4) no adverse event was reported after PSMA-11 injection, even associated with a contrast agent and/or furosemide.ConclusionCompared with the performance of PSMA-11 PET/CT in BCR reported independently of FCH PET/CT in 6 large published series (n > 200), the selection based on FCH PET/CT resulted in no difference of PSMA-11 PR for sPSA < 1 ng/mL but in a slightly lower PR for sPSA \u2265 1 ng/mL, probably because FCH performs rather well at this sPSA and very occult BCR was over-represented in our cohort. An oligometastatic pattern paving the way to targeted therapy was observed in one fourth to one third of the cases, according to the clinico-biochemical context of the BCR. Systematic dual or triple acquisition time points or administration of a contrast agent and/or furosemide did not bring a significant added value for PSMA-11 PET/CT positivity and should be decided on individual bases.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00259-020-05086-1", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1297401", 
            "issn": [
              "1619-7070", 
              "1619-7089"
            ], 
            "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "9", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "48"
          }
        ], 
        "keywords": [
          "FCH PET/CT", 
          "PSMA-11 PET/CT", 
          "serum PSA levels", 
          "PET/CT", 
          "biochemical recurrence", 
          "positivity rate", 
          "French Medicines Agency", 
          "prostate cancer", 
          "BCR patients", 
          "Medicines Agency", 
          "median serum PSA level", 
          "PET/CT positivity", 
          "overall positivity rate", 
          "time points", 
          "CT positivity rate", 
          "imaging protocol", 
          "higher positivity rate", 
          "dose-length product", 
          "low positivity rate", 
          "contrast agents", 
          "PSA levels", 
          "initial therapy", 
          "adverse events", 
          "CT positivity", 
          "superior diagnostic performance", 
          "multiple time points", 
          "targeted therapy", 
          "patients", 
          "diagnostic performance", 
          "CT", 
          "line PET/CT", 
          "clinical context", 
          "patient data", 
          "PSMA-11", 
          "furosemide", 
          "length product", 
          "acquisition time points", 
          "recurrence", 
          "significant differences", 
          "individual basis", 
          "cancer", 
          "therapy", 
          "administration", 
          "gallium-68", 
          "detection rate", 
          "site readings", 
          "FCH", 
          "agents", 
          "IntroductionDespite", 
          "short series", 
          "cases", 
          "cohort", 
          "protocol", 
          "positivity", 
          "total", 
          "ANSM", 
          "age", 
          "differences", 
          "injection", 
          "examination", 
          "rate", 
          "third", 
          "safety", 
          "aim", 
          "patterns", 
          "years", 
          "PET", 
          "evidence", 
          "center", 
          "data", 
          "levels", 
          "activity", 
          "image acquisition", 
          "events", 
          "series", 
          "tolerance", 
          "survey", 
          "use", 
          "authorisation", 
          "number", 
          "sites", 
          "France", 
          "point", 
          "agencies", 
          "acquisition", 
          "values", 
          "basis", 
          "context", 
          "selection", 
          "products", 
          "reading", 
          "performance", 
          "way"
        ], 
        "name": "Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations", 
        "pagination": "2935-2950", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1134446316"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00259-020-05086-1"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "33416958"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00259-020-05086-1", 
          "https://app.dimensions.ai/details/publication/pub.1134446316"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:08", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_922.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00259-020-05086-1"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-020-05086-1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-020-05086-1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-020-05086-1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-020-05086-1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    326 TRIPLES      21 PREDICATES      140 URIs      120 LITERALS      17 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00259-020-05086-1 schema:about N0eb155fbc39a496fa5c52869e6357dfe
    2 N2a09f8cbd77e44bfb49c94078d487b03
    3 N3ee8a6446c8146c39cb2fbbc7fd6e2a0
    4 N43a4b2a38f104353ba6c2a0a512700b7
    5 N4cc608efec08487da81046e52f630ec5
    6 N5d6331b914d449ea8d572b7b9924120d
    7 N5e7fa8786ce041f1b3858870808d4c5c
    8 N8ae3597e88d5426eb26c7af27c4569e9
    9 Nd6448181b6024cc58350d7dadc848f96
    10 Ne29d2af463ee41e193cb224b5f558f26
    11 anzsrc-for:11
    12 anzsrc-for:1103
    13 schema:author Nbbb6329077c94df58bced1bb142c6a7e
    14 schema:citation sg:pub.10.1007/s00259-013-2525-5
    15 sg:pub.10.1007/s00259-015-3240-1
    16 sg:pub.10.1007/s00259-016-3578-z
    17 sg:pub.10.1007/s00259-017-3670-z
    18 sg:pub.10.1007/s00259-017-3711-7
    19 sg:pub.10.1007/s00259-018-4067-3
    20 sg:pub.10.1007/s00259-018-4189-7
    21 sg:pub.10.1007/s00259-019-04505-2
    22 sg:pub.10.1007/s00259-019-04548-5
    23 sg:pub.10.1007/s00259-020-04718-w
    24 sg:pub.10.1007/s00259-020-04809-8
    25 sg:pub.10.1186/s13550-020-0595-5
    26 schema:datePublished 2021-01-08
    27 schema:datePublishedReg 2021-01-08
    28 schema:description IntroductionDespite growing evidence of a superior diagnostic performance of 68Ga-PSMA-11 over 18F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients. Our aims were to check (1) whether the excellent PR reported with PSMA-11 is also obtained in BCR patients whose recent FCH PET/CT was negative or equivocal; (2) in which biochemical and clinical context a high PSMA-11 PET/CT PR may be expected in those patients, in particular revealing an oligometastatic pattern; (3) whether among the various imaging protocols for PSMA-11 PET/CT used in France, one yields a significantly highest PR; (4) the tolerance of PSMA-11.Patients and methodsSix centres performed 68Ga-PSMA-11 PET/CTs during the first 3 years of its use in France. Prior to each PET/CT, the patient’s data were submitted prospectively for authorisation to ANSM, the French Medicine Agency. The on-site readings of 1084 PSMA-11 PET/CTs in BCR patients whose recent FCH PET/CTs resulted negative or equivocal were pooled and analysed.Results(1) The overall PR was 68%; for a median serum PSA level (sPSA) of 1.7 ng/mL, an oligometastatic pattern (1–3 foci) was observed in 31% of the cases overall; (2) PR was significantly related to sPSA (from 41% if < 0.2 ng/mL to 81% if ≥ 2 ng/mL), to patients’ age, to initial therapy (64% if prostatectomy vs. 85% without prostatectomy due to frequent foci in the prostate fossa), to whether FCH PET/CT was negative or equivocal (PR = 62% vs. 82%), and to previous BCR (PR = 63% for 1st BCR vs. 72% in case of previous BCR); (3) no significant difference in PR was found according to the imaging protocol: injected activity, administration of a contrast agent and/or of furosemide, dose length product, one single or multiple time points of image acquisition; (4) no adverse event was reported after PSMA-11 injection, even associated with a contrast agent and/or furosemide.ConclusionCompared with the performance of PSMA-11 PET/CT in BCR reported independently of FCH PET/CT in 6 large published series (n > 200), the selection based on FCH PET/CT resulted in no difference of PSMA-11 PR for sPSA < 1 ng/mL but in a slightly lower PR for sPSA ≥ 1 ng/mL, probably because FCH performs rather well at this sPSA and very occult BCR was over-represented in our cohort. An oligometastatic pattern paving the way to targeted therapy was observed in one fourth to one third of the cases, according to the clinico-biochemical context of the BCR. Systematic dual or triple acquisition time points or administration of a contrast agent and/or furosemide did not bring a significant added value for PSMA-11 PET/CT positivity and should be decided on individual bases.
    29 schema:genre article
    30 schema:isAccessibleForFree true
    31 schema:isPartOf N0b7eb70816a04bdab177b9f642e31db8
    32 N240aced883424690917df497375642fb
    33 sg:journal.1297401
    34 schema:keywords ANSM
    35 BCR patients
    36 CT
    37 CT positivity
    38 CT positivity rate
    39 FCH
    40 FCH PET/CT
    41 France
    42 French Medicines Agency
    43 IntroductionDespite
    44 Medicines Agency
    45 PET
    46 PET/CT
    47 PET/CT positivity
    48 PSA levels
    49 PSMA-11
    50 PSMA-11 PET/CT
    51 acquisition
    52 acquisition time points
    53 activity
    54 administration
    55 adverse events
    56 age
    57 agencies
    58 agents
    59 aim
    60 authorisation
    61 basis
    62 biochemical recurrence
    63 cancer
    64 cases
    65 center
    66 clinical context
    67 cohort
    68 context
    69 contrast agents
    70 data
    71 detection rate
    72 diagnostic performance
    73 differences
    74 dose-length product
    75 events
    76 evidence
    77 examination
    78 furosemide
    79 gallium-68
    80 higher positivity rate
    81 image acquisition
    82 imaging protocol
    83 individual basis
    84 initial therapy
    85 injection
    86 length product
    87 levels
    88 line PET/CT
    89 low positivity rate
    90 median serum PSA level
    91 multiple time points
    92 number
    93 overall positivity rate
    94 patient data
    95 patients
    96 patterns
    97 performance
    98 point
    99 positivity
    100 positivity rate
    101 products
    102 prostate cancer
    103 protocol
    104 rate
    105 reading
    106 recurrence
    107 safety
    108 selection
    109 series
    110 serum PSA levels
    111 short series
    112 significant differences
    113 site readings
    114 sites
    115 superior diagnostic performance
    116 survey
    117 targeted therapy
    118 therapy
    119 third
    120 time points
    121 tolerance
    122 total
    123 use
    124 values
    125 way
    126 years
    127 schema:name Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations
    128 schema:pagination 2935-2950
    129 schema:productId N66a4f3cc18294b429b8ea565b7025056
    130 Ne6d378b402a04389ae59a90c54500389
    131 Nfe71bbb477bb4363912c33f6956e3ca7
    132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134446316
    133 https://doi.org/10.1007/s00259-020-05086-1
    134 schema:sdDatePublished 2022-09-02T16:08
    135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    136 schema:sdPublisher N295024065d3e4dbdaf323d096641f239
    137 schema:url https://doi.org/10.1007/s00259-020-05086-1
    138 sgo:license sg:explorer/license/
    139 sgo:sdDataset articles
    140 rdf:type schema:ScholarlyArticle
    141 N094cab6d688c43f4b80adb543b984360 rdf:first sg:person.0577012270.46
    142 rdf:rest Nab38c78ea447457289bfc41ac05b66c4
    143 N0b7eb70816a04bdab177b9f642e31db8 schema:issueNumber 9
    144 rdf:type schema:PublicationIssue
    145 N0eb155fbc39a496fa5c52869e6357dfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name France
    147 rdf:type schema:DefinedTerm
    148 N1715ee55881a4cd1b528d41dc8353337 rdf:first sg:person.01121730347.36
    149 rdf:rest N9aac67ab99b14fda9acea4178f020304
    150 N240aced883424690917df497375642fb schema:volumeNumber 48
    151 rdf:type schema:PublicationVolume
    152 N295024065d3e4dbdaf323d096641f239 schema:name Springer Nature - SN SciGraph project
    153 rdf:type schema:Organization
    154 N29e5a10ecabd4cdbac336ce1827a1938 rdf:first sg:person.01203037034.35
    155 rdf:rest N33869d61af3c487dbfcfd21c92517f36
    156 N2a09f8cbd77e44bfb49c94078d487b03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Choline
    158 rdf:type schema:DefinedTerm
    159 N33869d61af3c487dbfcfd21c92517f36 rdf:first sg:person.0636003365.53
    160 rdf:rest N90dd563ccb954449b46d8d1bad0de4d3
    161 N3ee8a6446c8146c39cb2fbbc7fd6e2a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Gallium Isotopes
    163 rdf:type schema:DefinedTerm
    164 N43a4b2a38f104353ba6c2a0a512700b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Neoplasm Recurrence, Local
    166 rdf:type schema:DefinedTerm
    167 N4cc608efec08487da81046e52f630ec5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Male
    169 rdf:type schema:DefinedTerm
    170 N5d6331b914d449ea8d572b7b9924120d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Gallium Radioisotopes
    172 rdf:type schema:DefinedTerm
    173 N5e7fa8786ce041f1b3858870808d4c5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Positron Emission Tomography Computed Tomography
    175 rdf:type schema:DefinedTerm
    176 N66a4f3cc18294b429b8ea565b7025056 schema:name doi
    177 schema:value 10.1007/s00259-020-05086-1
    178 rdf:type schema:PropertyValue
    179 N767f5f53a525480087aa8a0fe223f18e rdf:first sg:person.012314332345.91
    180 rdf:rest N1715ee55881a4cd1b528d41dc8353337
    181 N8ae3597e88d5426eb26c7af27c4569e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Prostate-Specific Antigen
    183 rdf:type schema:DefinedTerm
    184 N90dd563ccb954449b46d8d1bad0de4d3 rdf:first sg:person.01307140060.86
    185 rdf:rest Nd7c78eeff25f4a978b6121648c31a70a
    186 N9aac67ab99b14fda9acea4178f020304 rdf:first sg:person.01240530667.47
    187 rdf:rest N29e5a10ecabd4cdbac336ce1827a1938
    188 Nab38c78ea447457289bfc41ac05b66c4 rdf:first sg:person.07715603712.83
    189 rdf:rest rdf:nil
    190 Nbbb6329077c94df58bced1bb142c6a7e rdf:first sg:person.013471630317.55
    191 rdf:rest N767f5f53a525480087aa8a0fe223f18e
    192 Nd6448181b6024cc58350d7dadc848f96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Humans
    194 rdf:type schema:DefinedTerm
    195 Nd7c78eeff25f4a978b6121648c31a70a rdf:first sg:person.0760027635.35
    196 rdf:rest N094cab6d688c43f4b80adb543b984360
    197 Ne29d2af463ee41e193cb224b5f558f26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Prostatic Neoplasms
    199 rdf:type schema:DefinedTerm
    200 Ne6d378b402a04389ae59a90c54500389 schema:name dimensions_id
    201 schema:value pub.1134446316
    202 rdf:type schema:PropertyValue
    203 Nfe71bbb477bb4363912c33f6956e3ca7 schema:name pubmed_id
    204 schema:value 33416958
    205 rdf:type schema:PropertyValue
    206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    207 schema:name Medical and Health Sciences
    208 rdf:type schema:DefinedTerm
    209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    210 schema:name Clinical Sciences
    211 rdf:type schema:DefinedTerm
    212 sg:journal.1297401 schema:issn 1619-7070
    213 1619-7089
    214 schema:name European Journal of Nuclear Medicine and Molecular Imaging
    215 schema:publisher Springer Nature
    216 rdf:type schema:Periodical
    217 sg:person.01121730347.36 schema:affiliation grid-institutes:grid.413483.9
    218 schema:familyName Gauthé
    219 schema:givenName Mathieu
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121730347.36
    221 rdf:type schema:Person
    222 sg:person.01203037034.35 schema:affiliation grid-institutes:grid.413852.9
    223 schema:familyName Skanjeti
    224 schema:givenName Andrea
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203037034.35
    226 rdf:type schema:Person
    227 sg:person.012314332345.91 schema:affiliation grid-institutes:grid.483743.f
    228 schema:familyName Boudali
    229 schema:givenName Lotfi
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012314332345.91
    231 rdf:type schema:Person
    232 sg:person.01240530667.47 schema:affiliation grid-institutes:grid.4817.a
    233 schema:familyName Rousseau
    234 schema:givenName Caroline
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
    236 rdf:type schema:Person
    237 sg:person.01307140060.86 schema:affiliation grid-institutes:None
    238 schema:familyName Robin
    239 schema:givenName Philippe
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307140060.86
    241 rdf:type schema:Person
    242 sg:person.013471630317.55 schema:affiliation grid-institutes:grid.483743.f
    243 schema:familyName Chevalme
    244 schema:givenName Yanna-Marina
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013471630317.55
    246 rdf:type schema:Person
    247 sg:person.0577012270.46 schema:affiliation grid-institutes:None
    248 schema:familyName Janier
    249 schema:givenName Marc
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577012270.46
    251 rdf:type schema:Person
    252 sg:person.0636003365.53 schema:affiliation grid-institutes:None
    253 schema:familyName Merlin
    254 schema:givenName Charles
    255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636003365.53
    256 rdf:type schema:Person
    257 sg:person.0760027635.35 schema:affiliation grid-institutes:grid.462282.8
    258 schema:familyName Giraudet
    259 schema:givenName Anne-Laure
    260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760027635.35
    261 rdf:type schema:Person
    262 sg:person.07715603712.83 schema:affiliation grid-institutes:None
    263 schema:familyName Talbot
    264 schema:givenName Jean-Noël
    265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07715603712.83
    266 rdf:type schema:Person
    267 sg:pub.10.1007/s00259-013-2525-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010481232
    268 https://doi.org/10.1007/s00259-013-2525-5
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1007/s00259-015-3240-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020308992
    271 https://doi.org/10.1007/s00259-015-3240-1
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1007/s00259-016-3578-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1002221535
    274 https://doi.org/10.1007/s00259-016-3578-z
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1007/s00259-017-3670-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1084020155
    277 https://doi.org/10.1007/s00259-017-3670-z
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1007/s00259-017-3711-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085391295
    280 https://doi.org/10.1007/s00259-017-3711-7
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1007/s00259-018-4067-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104899563
    283 https://doi.org/10.1007/s00259-018-4067-3
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1007/s00259-018-4189-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107767706
    286 https://doi.org/10.1007/s00259-018-4189-7
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1007/s00259-019-04505-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120901331
    289 https://doi.org/10.1007/s00259-019-04505-2
    290 rdf:type schema:CreativeWork
    291 sg:pub.10.1007/s00259-019-04548-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122256860
    292 https://doi.org/10.1007/s00259-019-04548-5
    293 rdf:type schema:CreativeWork
    294 sg:pub.10.1007/s00259-020-04718-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1125547439
    295 https://doi.org/10.1007/s00259-020-04718-w
    296 rdf:type schema:CreativeWork
    297 sg:pub.10.1007/s00259-020-04809-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1126836112
    298 https://doi.org/10.1007/s00259-020-04809-8
    299 rdf:type schema:CreativeWork
    300 sg:pub.10.1186/s13550-020-0595-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124553996
    301 https://doi.org/10.1186/s13550-020-0595-5
    302 rdf:type schema:CreativeWork
    303 grid-institutes:None schema:alternateName Comité permanent de l’ANSM, Médicaments de diagnostic et de médecine nucléaire, St Denis, France
    304 Nuclear Medicine Department, Cancer Center Jean PERRIN, Clermont-Ferrand, France
    305 Service de Médecine Nucléaire, EA 3878 (GETBO), Centre Hospitalier Régional et Universitaire de Brest, Université de Bretagne Occidentale, Brest, France
    306 schema:name Comité permanent de l’ANSM, Médicaments de diagnostic et de médecine nucléaire, St Denis, France
    307 Nuclear Medicine Department, Cancer Center Jean PERRIN, Clermont-Ferrand, France
    308 Nuclear Medicine Department, Hospices Civils de Lyon, EA 3738, Université Claude Bernard Lyon 1, Lyon, France
    309 Service de Médecine Nucléaire, EA 3878 (GETBO), Centre Hospitalier Régional et Universitaire de Brest, Université de Bretagne Occidentale, Brest, France
    310 Service de médecine nucléaire, Hôpital Tenon, AP-HP Sorbonne Université, Paris, France
    311 rdf:type schema:Organization
    312 grid-institutes:grid.413483.9 schema:alternateName Service de médecine nucléaire, Hôpital Tenon, AP-HP Sorbonne Université, Paris, France
    313 schema:name Service de médecine nucléaire, Hôpital Tenon, AP-HP Sorbonne Université, Paris, France
    314 rdf:type schema:Organization
    315 grid-institutes:grid.413852.9 schema:alternateName Nuclear Medicine Department, Hospices Civils de Lyon, EA 3738, Université Claude Bernard Lyon 1, Lyon, France
    316 schema:name Nuclear Medicine Department, Hospices Civils de Lyon, EA 3738, Université Claude Bernard Lyon 1, Lyon, France
    317 rdf:type schema:Organization
    318 grid-institutes:grid.462282.8 schema:alternateName Nuclear Medicine Department LUMEN, Léon Bérard Cancer Center, Lyon, France
    319 schema:name Nuclear Medicine Department LUMEN, Léon Bérard Cancer Center, Lyon, France
    320 rdf:type schema:Organization
    321 grid-institutes:grid.4817.a schema:alternateName Nuclear Medicine Unit, ICO René Gauducheau, CNRS, Inserm, CRCINA, Nantes University, F-44000, Nantes, France
    322 schema:name Nuclear Medicine Unit, ICO René Gauducheau, CNRS, Inserm, CRCINA, Nantes University, F-44000, Nantes, France
    323 rdf:type schema:Organization
    324 grid-institutes:grid.483743.f schema:alternateName Direction des médicaments en oncologie, hématologie, transplantation, néphrologie, thérapie cellulaire, produits sanguins, et radiopharmaceutiques, Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), 143 Bd Anatole, F93200, St Denis, France
    325 schema:name Direction des médicaments en oncologie, hématologie, transplantation, néphrologie, thérapie cellulaire, produits sanguins, et radiopharmaceutiques, Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), 143 Bd Anatole, F93200, St Denis, France
    326 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...